The estimated Net Worth of Nancy A Simonian is at least $3.85 Millón dollars as of 31 March 2024. Nancy Simonian owns over 45,566 units of Syros Pharmaceuticals stock worth over $234,593 and over the last 19 years he sold SYRS stock worth over $0. In addition, he makes $3,614,020 as President, Chief Executive Officer y Director at Syros Pharmaceuticals.
Sign up
Nancy Simonian SYRS stock SEC Form 4 insiders trading
Nancy has made over 8 trades of the Syros Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 45,566 units of SYRS stock worth $73,361 on 31 March 2024.
The largest trade he's ever made was exercising 110,588 units of Syros Pharmaceuticals stock on 29 November 2018 worth over $136,023. On average, Nancy trades about 7,403 units every 45 days since 2006. As of 31 March 2024 he still owns at least 145,710 units of Syros Pharmaceuticals stock.
You can see the complete history of Nancy Simonian stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Nancy Simonian biography
Dr. Nancy A. Simonian M.D. serves as President, Chief Executive Officer, Director of the Company. From 2001 to October 2011, Dr. Simonian was employed by Takeda Pharmaceuticals Company, a publicly-held biopharmaceutical company, and at Millennium Pharmaceuticals, Inc. prior to its acquisition by Takeda, most recently as chief medical officer and senior vice president of clinical, medical and regulatory affairs. From 1995 to 2001, Dr. Simonian served at Biogen, Inc., a publicly-held biotechnology company, most recently as vice president of clinical development. She is a member of the boards of directors of Seattle Genetics, Inc., a biotechnology company, the Damon Runyon Cancer Research Foundation and the Biotechnology Industry Organization. Prior to joining the biopharmaceutical industry, Dr. Simonian was on the faculty of Massachusetts General Hospital and Harvard Medical School as an assistant professor of neurology. She received a B.A. in biology from Princeton University and an M.D. from the University of Pennsylvania School of Medicine. Simonian is qualified to serve on our board because of her role as our chief executive officer, her experience in the biopharmaceutical industry and her other executive leadership and board of directors experience.
What is the salary of Nancy Simonian?
As the President, Chief Executive Officer y Director of Syros Pharmaceuticals, the total compensation of Nancy Simonian at Syros Pharmaceuticals is $3,614,020. There are no executives at Syros Pharmaceuticals getting paid more.
How old is Nancy Simonian?
Nancy Simonian is 59, he's been the President, Chief Executive Officer y Director of Syros Pharmaceuticals since 2018. There are 10 older and 9 younger executives at Syros Pharmaceuticals. The oldest executive at Syros Pharmaceuticals Inc. is Phillip Sharp, 75, who is the Independent Director.
What's Nancy Simonian's mailing address?
Nancy's mailing address filed with the SEC is C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE, MA, 02140.
Insiders trading at Syros Pharmaceuticals
Over the last 8 years, insiders at Syros Pharmaceuticals have traded over $8,259,551 worth of Syros Pharmaceuticals stock and bought 5,052,185 units worth $51,830,966 . The most active insiders traders include Group, Llc Green Jeremy Red..., Srinivas Akkaraju y Stephane Bancel. On average, Syros Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $135,148. The most recent stock trade was executed by Richard A Young on 28 June 2024, trading 34,837 units of SYRS stock currently worth $178,365.
What does Syros Pharmaceuticals do?
syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
What does Syros Pharmaceuticals's logo look like?
Complete history of Nancy Simonian stock trades at Seagen Inc, Syros Pharmaceuticals y Evelo Biosciences Inc
Syros Pharmaceuticals executives and stock owners
Syros Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Nancy Simonian,
President, Chief Executive Officer, Director -
Joseph Ferra,
Chief Financial Officer -
Jeremy Springhorn,
Chief Business Officer -
David Roth,
Chief Medical Officer -
Eric Olson,
Chief Scientific Officer -
Gerald Quirk,
Chief Legal & Administrative Officer -
Dr. Nancy A. Simonian M.D.,
Pres, CEO & Director -
Dr. David A. Roth,
Chief Medical Officer -
Dr. Eric R. Olson,
Chief Scientific Officer -
Richard Young,
Director -
Dr. Richard A. Young Ph.D.,
Scientific Founder, Member of Scientific Advisory Board & Director -
Mark Alles,
Independent Director -
Peter Wirth,
Independent Chairman of the Board -
Marsha Fanucci,
Independent Director -
Amir Nashat,
Independent Director -
Phillip Sharp,
Independent Director -
Srinivas Akkaraju,
Independent Director -
Hannah Deresiewicz,
IR Contact Officer -
S. Gail Eckhardt,
Director -
Dr. Christian C. Fritz Ph.D.,
Head of Biology -
Naomi Aoki,
VP of Corp. Communications & Investor Relations -
Gerald E. Quirk,
Chief Operations Officer & Sec. -
Jason Haas,
Chief Financial Officer -
Dr. Nathanael S. Gray Ph.D.,
Scientific Founder & Member of Scientific Advisory Board -
Dr. James E. Bradner M.D.,
Founder -
Alice Tsang Shaw,
Director -
Ventures Fund Iv, L.P.Flags...,
-
Sanj K Patel,
Director -
Vicki L Sato,
Director -
Michael W Bonney,
Director -
Colleen Elizabeth De Simone,
Principal Accounting Officer -
Robert Nelsen,
Director -
Venture Fund Vii, L.P.Arch ...,
-
Kyle D. Kuvalanka,
Chief Operating Officer -
Stephane Bancel,
Director -
Management Co. Vii, L.L.C.P...,
-
Pharm Tech Healthcare Fund ...,
10% owner -
Group, Llc Green Jeremy Red...,
-
Venture Fund Vii Lparch Ven...,
-
Healthcare Ventures Ii, L.P...,
10% owner -
James E Deerfield Mgmt L.P....,
-
Kristin Stephens,
Chief Development Officer -
Deborah Dunsire,
-
Jason Haas,
Chief Financial Officer -
Timothy Tyson,
-
Conley Chee,
President & CEO -
Andrew M. Oh,